This study investigated the short term effects (6 days) of recombinant human growth hormone (rhGH) administration (0.056 mg/kg/day) and weight training on arterial pulse wave velocity (APWV), homocysteine (HCY) and high sensitivity C-reactive protein (C-RP) in weight training individuals and matched exercising controls. APWV a non-invasive method for measuring atherosclerotic and hypertensive vascular changes increases with age and atherosclerosis leading to increased systolic blood pressure (BP) and increased left ventricular hypertrophy. Aerobic exercise training increases arterial compliance and reduces systolic blood pressure (Kingwell et al. 1997). Whole body arterial compliance is lowered in strength-trained individuals (Bertovic et al. 1999). Arterial endothelial dysfunction (an accepted cause of decreased arterial compliance) in growth hormone deficiency is reversed by growth hormone (rhGH) therapy, which favourably influences the risk for atherogenesis (Lilien et al. 2004). Both HCY and C-RP are two inflammatory markers directly linked with arterial endothelial dysfunction and increased APWV (Bortolotto et al. 1999; Nagano et al. 2004). The subjects who participated in this study, were twenty four self-prescribing weight lifters (rhGH), aged between 20 and 48 years. Their results were compared with twenty four non-drug using age-matched exercise controls (EC). The dosages were administered under the supervision of the authors (morning administration), before any training sessions. All dosages used were recorded in an administration diary. Group differences were analysed using a two-way (group x time) repeated measures ANOVA at three time points, pre-rhGH administration (day 1), on-rhGH (day 7), post-rhGH administration (day 7). Between group differences were analysed using an independent t test. Within group differences were analysed using a paired t test followed by a post-hoc Bonferroni test. APWV (ms-1), HCY and C-RP concentrations diminished within the rhGH administration group (APWV: 9.97 ± 1.38 vs. 9.18 ± 1.6 vs. 9.26 ± 1.52, ms-1, p<0.05; HCY: 13.2 ± 4.0 vs. 11.7 ± 3.1 vs. 13.1 ± 4.3 μmol/l; hsC-RP: 1.77 ± 2.1 vs. 1.29 ± 1.6 vs. 1.7 ± 2.8 mg/l, p<0.01) but not in the EC group when the two were compared. RhGH administration resulted in an increase in serum Insulin like growth factor-1 within the rhGH group (159 ± 54 vs. 323 ± 93 vs.175 ± 61 μmol/l, p<0.001) and compared with the EC group (323 ± 93 vs. 169 ± 50 μmol/l, p<0.001) demonstrating that the growth hormone was responsible for the physiological effects. In conclusion short term use of rhGH altered APWV, HCY and hsC-RP favourably, opening up a series of ethical dilemmas on management of the somatopause. All data are means ± SD.